May 12, 2022 4:05pm EDT iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update
May 09, 2022 8:00am EDT iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
May 05, 2022 4:30pm EDT iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
May 02, 2022 8:00am EDT iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
Feb 14, 2022 4:05pm EST iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update
Feb 07, 2022 4:30pm EST iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022
Jan 26, 2022 9:00am EST iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease
Dec 22, 2021 9:25am EST iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022
